Yi Yao | Nanomedicine | Best Researcher Award Published on 16/09/2025 by ScienceFather Prof. Yi Yao | Nanomedicine | Best Researcher Award Renmin Hospital of Wuhan University | China Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research. Profile: Orcid Featured publications Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76. Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298. Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309. Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567. Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926. Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.
Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research. Profile: Orcid Featured publications Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76. Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298. Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309. Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567. Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926. Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.